Anavex Life Sciences Corp (AVXL) has a current Price-to-Book (P/B) ratio of 3.36. Compared to its 3-year average P/B ratio of 5.18, the current P/B ratio is approximately -35.16% higher. Relative to its 5-year average P/B ratio of 6.47, the current P/B ratio is about -48.04% higher. Anavex Life Sciences Corp (AVXL) has a Forward Free Cash Flow (FCF) yield of approximately -11.87%. Compared to its 3-year average FCF yield of -5.54%, the current FCF yield is approximately 114.21% lower. Relative to its 5-year average FCF yield of -4.42%, the current FCF yield is about 168.61% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for AVXL competitors is -1.69, providing a benchmark for relative valuation. Anavex Life Sciences Corp Corp (AVXL.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of AVXL increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of AVXL in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is AVXL currently overvalued or undervalued?

What is Anavex Life Sciences Corp (AVXL) fair value?

AVXL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Anavex Life Sciences Corp (AVXL) is between NaN to NaN according to relative valuation method.

How does AVXL's valuation metrics compare to the industry average?

The average P/S ratio for AVXL's competitors is -1.69, providing a benchmark for relative valuation. Anavex Life Sciences Corp Corp (AVXL) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Anavex Life Sciences Corp (AVXL) as of Mar 03 2026?

As of Mar 03 2026, Anavex Life Sciences Corp (AVXL) has a P/B ratio of 3.36. This indicates that the market values AVXL at 3.36 times its book value.

What is the current FCF Yield for Anavex Life Sciences Corp (AVXL) as of Mar 03 2026?

As of Mar 03 2026, Anavex Life Sciences Corp (AVXL) has a FCF Yield of -11.87%. This means that for every dollar of Anavex Life Sciences Corp's market capitalization, the company generates -11.87 cents in free cash flow.

What is the current Forward P/E ratio for Anavex Life Sciences Corp (AVXL) as of Mar 03 2026?

As of Mar 03 2026, Anavex Life Sciences Corp (AVXL) has a Forward P/E ratio of -7.67. This means the market is willing to pay $-7.67 for every dollar of Anavex Life Sciences Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Anavex Life Sciences Corp (AVXL) as of Mar 03 2026?

As of Mar 03 2026, Anavex Life Sciences Corp (AVXL) has a Forward P/S ratio of 0.00. This means the market is valuing AVXL at $0.00 for every dollar of expected revenue over the next 12 months.

AVXL Valuation